Additional identifiers
EudraCT/CTIS number
IRAS number
ClinicalTrials.gov number
Protocol/serial number
7554; G0801443
Study information
Scientific title
Cortisol hyper-reactivity to stress - a putative biomarker for major depressive disorder
Acronym
Study hypothesis
1. Cortisol hyper-reactivity is differentially present in individuals at high risk for depression
2. Cortisol hyper-reactivity is associated with negative cognitive biases proven to be associated with depression
3. Cortisol reactivity to stress is more strongly associated with risk factors for depression than are basal measures of cortisol
Ethics approval(s)
Cambridgeshire 2 REC, 18/06/2009, ref: 09/H0308/69
Study design
Single-centre screening clinical laboratory study
Primary study design
Observational
Secondary study design
Single-centre
Study setting(s)
Hospital
Study type
Screening
Patient information sheet
Not available in web format, please use the contact details below to request a patient information sheet
Condition
Topic: Mental Health Research Network; Subtopic: Depression, Stress-related and somatoform; Disease: Depression, Stress-related and somatoform disorders
Intervention
35% Carbon Dioxide Vital Capacity Inhalation Stress Test:
Participants insert the mouthpiece into their mouth. The three-way valve is set so they are breathing air. The experimenter asks the participant to breathe fully out, then take a breath as deep as they can, and hold it for 4 seconds, as a practice. The valve is changed so the CO2 tank is connected to the bag reservoir. The reservoir is filled. The valve is changed so the mouthpiece is attached to the CO2 in the reservoir. The participant breathes in and holds as with the practice.
Trier Social Stress Test:
The experimenter leads the participant to the experimental room at time 0, where they are introduced to two people (the 'committee'), a microphone and a video-camera. The experimenter tells the participant that they will have to deliver a speech for a job application to the committee, followed by another task, that will be detailed then. They are given instructions by the committee, then prepare their speech until T +3 min. They are asked to deliver the speech. If they stop before 5 minutes, or their speech is not relevant, there are standard questions and prompts. Then they are asked to do the second task, where they must serially subtract 13 from 1022 as quickly and accurately as possible. After mistakes, they are asked return to 1022 and re-start. This lasts 5 minutes, then the task ends.
Each test happens once, and follow-up is for 60 minutes after start of test.
Intervention type
Other
Primary outcome measure
Salivary cortisol area under the curve in the time period after intervention, collected 20 minutes before and immediately before, and 20, 30, 40 and 60 minutes after, the onset of each stress test.
Secondary outcome measures
1. Performance on affective go:no go, measured at rest (before first stress test) and 30 minutes after the start of each stress test
2. Ratio of negative to positive words correctly recalled, measured at rest (before first stress test) and 25 minutes after the start of each stress test
3. Which stress test leads to largest rise in cortisol?
Overall study start date
13/04/2010
Overall study end date
31/01/2012
Reason abandoned (if study stopped)
Eligibility
Participant inclusion criteria
1. Aged 16 - 21 years old
2. Male and female
3. Recruited from Roots study
Participant type(s)
Patient
Age group
Adult
Sex
Both
Target number of participants
Planned sample size: 228
Participant exclusion criteria
1. Take regular steroid medication (oral or inhaled) or take hormonal contraceptives containing oestrogens (combined pill, injection, implant or patch)
2. Hypertension requiring regular treatment
3. Systolic blood pressure above 140 mmHg or resting pulse over 100 mmHg at the start of the study
4. Current respiratory disease, e.g., asthma
5. A personal or family history (parent or sibling) of panic disorder
6. Significant claustrophobia
7. Smoke daily; no smoking on day of assessment
8. Migraine within the last year
9. Current heart disease
10. Females will be excluded if they are or think they might be pregnant, are lactating, or their menstrual cycle has not returned to being regular after pregnancy
11. At least one biological grandparent known to be non-white European
12. At least one of the following psychiatric disorders at time of interview: anxiety disorder, OCD, oppositional defiant disorder, PTSD, conduct disorder, bipolar disorder
13. Alcohol or illicit drug use on the day of or the day before research assessment
14. Caffeine use since breakfast on the day of research assessment
15. Consume large amounts of caffeinated drinks on a regular basis (greater than six cups of coffee per day or drinks containing methylxanthines such as Pepsi or red bull)
16. Current severe cold or flu
17. Vigorous exercise for 2 hours before testing
Additional group-specific criteria:
18. Never-depressed participants:
18.1. No lifetime history of major depressive disorder
18.2. No lifetime history of at least one of the following psychiatric disorders: anxiety disorder, OCD, oppositional defiant disorder, PTSD, conduct disorder, bipolar disorder, ADHD
19. Recovered-depressed:
19.1. At least one past episode of major depressive disorder
19.2. At least 8 weeks of having fewer than two depressive symptoms since last episode
19.3. Not currently taking antidepressants
19.4. No lifetime history of ADHD, autism, conduct disorder with onset before age 11
Recruitment start date
13/04/2010
Recruitment end date
31/01/2012
Locations
Countries of recruitment
England, United Kingdom
Study participating centre
Developmental Psychiatry Section
Cambridge
CB2 8AH
United Kingdom
Sponsor information
Organisation
Cambridgeshire and Peterborough NHS Foundation Trust (UK)
Sponsor details
Cambridge Road
Fulbourn
Cambridge
CB21 5EF
England
United Kingdom
--
natercia.godinho@cpft.nhs.uk
Sponsor type
Hospital/treatment centre
Website
ROR
Funders
Funder type
Research council
Funder name
Medical Research Council (MRC) (UK) (ref: G0801443)
Alternative name(s)
UK Medical Research Council, MRC
Funding Body Type
government organisation
Funding Body Subtype
National government
Location
United Kingdom
Results and Publications
Publication and dissemination plan
Not provided at time of registration
Intention to publish date
Individual participant data (IPD) sharing plan
IPD sharing plan summary
Not provided at time of registration
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|